alfuzosin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antihypertensive substances, prazosin derivatives	115	81403-80-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: alfuzosin alfuzosin hydrochloride xatral SL 77 alfuzosin HCl	Alfuzosin is a selective antagonist of post-synaptic alpha1-adrenoreceptors, which are located in the prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra. Molecular weight: 389.46 Formula: C19H27N5O4 CLOGP: 2.35 LIPINSKI: 0 HAC: 9 HDO: 2 TPSA: 111.83 ALOGS: -3.14 ROTB: 8 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

alfuzosin
alfuzosin hydrochloride
xatral
SL 77
alfuzosin HCl

Alfuzosin is a selective antagonist of post-synaptic alpha1-adrenoreceptors, which are located in the prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra.

Molecular weight: 389.46
Formula: C19H27N5O4
CLOGP: 2.35
LIPINSKI: 0
HAC: 9
HDO: 2
TPSA: 111.83
ALOGS: -3.14
ROTB: 8

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
7.50	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	11 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.34 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	55 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.50 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	5.90 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.14 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	4.80 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
June 12, 2003	FDA	COVIS PHARMA SARL

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Apraxia	66.68	43.57	13	983	1808	63486218
Dementia	60.62	43.57	19	977	18775	63469251
Disorientation	53.84	43.57	21	975	39431	63448595
Perseveration	52.24	43.57	8	988	267	63487759

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug dispensed to wrong patient	182.05	13.52	45	19428	479	34936979
Orthostatic hypotension	119.97	13.52	106	19367	25813	34911645
Acute kidney injury	117.28	13.52	404	19069	304584	34632874
Antimicrobial susceptibility test resistant	114.37	13.52	29	19444	345	34937113
Syncope	111.54	13.52	190	19283	91261	34846197
Minimum inhibitory concentration	101.87	13.52	23	19450	159	34937299
Wrong patient received product	100.08	13.52	42	19431	2612	34934846
Therapeutic response delayed	94.64	13.52	28	19445	610	34936848
Fall	77.04	13.52	268	19205	202617	34734841
Cholestasis	67.31	13.52	79	19394	26869	34910589
Confusional state	65.95	13.52	203	19270	143957	34793501
Hepatocellular injury	63.77	13.52	70	19403	22141	34915317
Hypotension	62.15	13.52	266	19207	221383	34716075
Wrong product administered	59.31	13.52	37	19436	5297	34932161
Agranulocytosis	58.11	13.52	69	19404	23752	34913706
Toxicity to various agents	55.74	13.52	21	19452	200341	34737117
Product storage error	53.93	13.52	41	19432	8081	34929377
Urinary retention	53.14	13.52	82	19391	36206	34901252
Product dispensing error	51.48	13.52	36	19437	6238	34931220
Coma	50.52	13.52	91	19382	45587	34891871
Expired product administered	47.09	13.52	27	19446	3314	34934144
Drug interaction	45.77	13.52	247	19226	225699	34711759
Eosinophilia	43.75	13.52	63	19410	26159	34911299
Product administration error	42.62	13.52	49	19424	16295	34921163
Thrombocytopenia	42.54	13.52	186	19287	156061	34781397
Pemphigoid	41.18	13.52	36	19437	8630	34928828
Allergy to animal	39.81	13.52	13	19460	396	34937062
Staring	38.45	13.52	18	19455	1452	34936006
Disorganised speech	36.40	13.52	15	19458	890	34936568
Growth hormone deficiency	35.45	13.52	11	19462	283	34937175
Completed suicide	33.35	13.52	7	19466	98161	34839297
Cell death	30.45	13.52	18	19455	2339	34935119
Cardiovascular insufficiency	30.30	13.52	16	19457	1671	34935787
Brain stem haematoma	29.35	13.52	8	19465	128	34937330
Daydreaming	28.51	13.52	11	19462	549	34936909
Nasal discomfort	28.00	13.52	15	19458	1613	34935845
Melaena	27.67	13.52	61	19412	35319	34902139
Bradycardia	27.10	13.52	98	19375	75320	34862138
Pituitary tumour benign	26.85	13.52	12	19461	869	34936589
Campylobacter gastroenteritis	26.85	13.52	12	19461	869	34936589
Petit mal epilepsy	26.04	13.52	18	19455	3060	34934398
Vertigo	25.86	13.52	49	19424	25487	34911971
Parkinsonism	25.73	13.52	27	19446	8111	34929347
Blood thyroid stimulating hormone decreased	25.54	13.52	15	19458	1926	34935532
Dermatitis exfoliative generalised	25.24	13.52	19	19454	3688	34933770
Neutropenia	24.34	13.52	160	19313	156618	34780840
Post procedural haemorrhage	23.56	13.52	26	19447	8263	34929195
Subileus	23.11	13.52	17	19456	3186	34934272
Hyperlipasaemia	22.44	13.52	9	19464	498	34936960
Altered state of consciousness	22.04	13.52	43	19430	22850	34914608
Toxic skin eruption	21.44	13.52	29	19444	11356	34926102
Incontinence	21.40	13.52	21	19452	5826	34931632
Hyponatraemia	21.37	13.52	97	19376	82594	34854864
Steroid diabetes	21.36	13.52	14	19459	2181	34935277
Illusion	21.24	13.52	10	19463	817	34936641
Diffuse large B-cell lymphoma recurrent	20.78	13.52	16	19457	3212	34934246
Hepatitis	20.75	13.52	43	19430	23861	34913597
Capillary fragility	20.69	13.52	5	19468	48	34937410
Atrioventricular block second degree	20.59	13.52	17	19456	3771	34933687
Purpura	20.54	13.52	27	19446	10284	34927174
Febrile bone marrow aplasia	20.37	13.52	24	19449	8185	34929273
Dysuria	20.32	13.52	46	19427	27106	34910352
On and off phenomenon	19.72	13.52	14	19459	2483	34934975
Generalised onset non-motor seizure	19.55	13.52	4	19469	16	34937442
Hypokalaemia	19.53	13.52	74	19399	58140	34879318
Hepatitis cholestatic	19.34	13.52	23	19450	7924	34929534
Febrile neutropenia	19.26	13.52	29	19444	136820	34800638
Soft tissue mass	19.26	13.52	10	19463	1009	34936449
Hanging	18.85	13.52	6	19467	168	34937290
Haemoglobinaemia	18.75	13.52	6	19467	171	34937287
Anaemia	18.53	13.52	205	19268	233130	34704328
Stool analysis abnormal	18.52	13.52	5	19468	77	34937381
Normocytic anaemia	18.19	13.52	13	19460	2331	34935127
Pancreatitis acute	18.15	13.52	45	19428	28096	34909362
Hypovolaemic shock	18.06	13.52	21	19452	7064	34930394
Dizziness	17.81	13.52	193	19280	218328	34719130
Loss of consciousness	17.77	13.52	92	19381	82575	34854883
Hallucination	17.71	13.52	66	19407	51432	34886026
Prostatomegaly	17.38	13.52	18	19455	5323	34932135
Dissociation	17.18	13.52	11	19462	1647	34935811
Vitamin B12 decreased	17.17	13.52	10	19463	1263	34936195
Pelvic fracture	17.13	13.52	13	19460	2554	34934904
Angina pectoris	17.01	13.52	47	19426	31316	34906142
Hallucination, visual	16.62	13.52	33	19440	17758	34919700
Hypernatraemia	16.56	13.52	22	19451	8468	34928990
Acquired haemophilia	16.52	13.52	9	19464	1001	34936457
Tonic clonic movements	16.44	13.52	9	19464	1010	34936448
Dyspnoea at rest	16.40	13.52	15	19458	3813	34933645
Cardiac failure congestive	15.64	13.52	14	19459	83256	34854202
Death	15.30	13.52	145	19328	397904	34539554
Behaviour disorder	15.00	13.52	16	19457	4894	34932564
Inappropriate antidiuretic hormone secretion	14.85	13.52	26	19447	12727	34924731
Amaurosis fugax	14.79	13.52	7	19466	579	34936879
Cystitis interstitial	14.79	13.52	5	19468	170	34937288
Subcapsular splenic haematoma	14.74	13.52	4	19469	63	34937395
Hyperkeratosis	14.73	13.52	14	19459	3735	34933723
Ketonuria	14.51	13.52	7	19466	604	34936854
Drug ineffective	13.73	13.52	176	19297	456575	34480883
Blood pressure decreased	13.72	13.52	61	19412	51454	34886004
Retrograde ejaculation	13.53	13.52	6	19467	427	34937031

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute kidney injury	208.49	15.10	393	17180	519011	79207804
Antimicrobial susceptibility test resistant	134.27	15.10	28	17545	360	79726455
Drug dispensed to wrong patient	128.04	15.10	30	17543	676	79726139
Minimum inhibitory concentration	123.40	15.10	23	17550	157	79726658
Orthostatic hypotension	115.29	15.10	97	17476	56067	79670748
Syncope	115.03	15.10	168	17405	179281	79547534
Drug interaction	109.18	15.10	265	17308	414918	79311897
Therapeutic response delayed	99.51	15.10	27	17546	1115	79725700
Cholestasis	90.82	15.10	82	17491	52027	79674788
Agranulocytosis	86.74	15.10	75	17498	44955	79681860
Confusional state	86.73	15.10	206	17367	317791	79409024
Wrong patient received product	86.35	15.10	34	17539	4584	79722231
Hypotension	82.41	15.10	248	17325	440069	79286746
Wrong product administered	76.18	15.10	38	17535	8974	79717841
Fall	75.20	15.10	257	17316	487372	79239443
Thrombocytopenia	74.64	15.10	174	17399	265085	79461730
Coma	74.47	15.10	101	17472	100548	79626267
Hepatocellular injury	73.47	15.10	70	17503	47523	79679292
Urinary retention	66.77	15.10	72	17501	56558	79670257
Eosinophilia	59.42	15.10	61	17512	45284	79681531
Neutropenia	56.51	15.10	165	17408	287545	79439270
Pemphigoid	52.62	15.10	36	17537	15279	79711536
Product dispensing error	52.38	15.10	34	17539	13229	79713586
Expired product administered	51.66	15.10	27	17546	7024	79719791
Product administration error	45.68	15.10	45	17528	31801	79695014
Hallucination, visual	44.64	15.10	45	17528	32684	79694131
Staring	44.33	15.10	18	17555	2627	79724188
Bradycardia	43.75	15.10	94	17479	135463	79591352
Growth hormone deficiency	41.37	15.10	11	17562	420	79726395
Pain	41.31	15.10	57	17516	703745	79023070
Product storage error	39.55	15.10	31	17542	16195	79710620
Disorganised speech	37.53	15.10	15	17558	2102	79724713
Melaena	37.48	15.10	56	17517	60834	79665981
Alopecia	36.87	15.10	4	17569	231351	79495464
Drug intolerance	36.45	15.10	7	17566	264112	79462703
Allergy to animal	35.60	15.10	13	17560	1426	79725389
Completed suicide	35.02	15.10	6	17567	245761	79481054
Hyponatraemia	34.87	15.10	102	17471	177746	79549069
Cell death	34.44	15.10	18	17555	4681	79722134
Hyperkalaemia	34.26	15.10	77	17496	114321	79612494
Daydreaming	32.99	15.10	11	17562	922	79725893
Cardiovascular insufficiency	32.59	15.10	15	17558	2966	79723849
Campylobacter gastroenteritis	32.54	15.10	12	17561	1353	79725462
Altered state of consciousness	32.42	15.10	44	17529	43778	79683037
Headache	31.72	15.10	60	17513	653712	79073103
Brain stem haematoma	31.47	15.10	7	17566	124	79726691
Petit mal epilepsy	31.11	15.10	18	17555	5709	79721106
Parkinsonism	30.67	15.10	27	17546	16557	79710258
Rheumatoid arthritis	29.90	15.10	5	17568	208465	79518350
Dermatitis exfoliative generalised	29.67	15.10	19	17554	7222	79719593
Pancreatitis acute	29.64	15.10	45	17528	49559	79677256
Toxic skin eruption	29.21	15.10	30	17543	22263	79704552
Hepatitis cholestatic	28.56	15.10	24	17549	13828	79712987
Perseveration	28.22	15.10	8	17565	389	79726426
Disorientation	28.12	15.10	50	17523	62726	79664089
Infusion related reaction	28.01	15.10	8	17565	230229	79496586
Toxicity to various agents	27.98	15.10	31	17542	421509	79305306
Prostatomegaly	27.42	15.10	14	17559	3469	79723346
Steroid diabetes	27.34	15.10	14	17559	3492	79723323
Haematuria	27.27	15.10	52	17521	68784	79658031
Hepatitis	27.06	15.10	46	17527	55681	79671134
Treatment failure	27.02	15.10	3	17570	170483	79556332
Apraxia	26.95	15.10	13	17560	2854	79723961
Soft tissue mass	25.91	15.10	10	17563	1278	79725537
Febrile bone marrow aplasia	25.69	15.10	22	17551	12998	79713817
Pituitary tumour benign	25.19	15.10	12	17561	2564	79724251
Purpura	25.08	15.10	26	17547	19501	79707314
Hypovolaemic shock	24.75	15.10	21	17552	12255	79714560
Atrioventricular block second degree	24.67	15.10	17	17556	7295	79719520
Status epilepticus	24.65	15.10	29	17544	25012	79701803
Behaviour disorder	24.48	15.10	16	17557	6297	79720518
Swelling	23.78	15.10	9	17564	216702	79510113
Hallucination	23.78	15.10	56	17517	85689	79641126
Subileus	23.57	15.10	15	17558	5639	79721176
Tonic clonic movements	23.53	15.10	11	17562	2253	79724562
Inappropriate antidiuretic hormone secretion	23.50	15.10	29	17544	26284	79700531
Blood thyroid stimulating hormone decreased	23.42	15.10	15	17558	5701	79721114
Therapeutic product effect decreased	23.34	15.10	4	17569	163859	79562956
Dehydration	23.07	15.10	112	17461	248075	79478740
Illusion	22.99	15.10	10	17563	1731	79725084
Anaemia	22.86	15.10	172	17401	444843	79281972
Hyperlipasaemia	22.63	15.10	9	17564	1245	79725570
On and off phenomenon	22.58	15.10	12	17561	3228	79723587
Pneumonia aspiration	22.23	15.10	47	17526	66920	79659895
Abdominal discomfort	22.08	15.10	14	17559	250713	79476102
Nasal discomfort	21.51	15.10	14	17559	5469	79721346
Haemoglobinaemia	21.24	15.10	6	17567	288	79726527
Bicytopenia	21.00	15.10	13	17560	4657	79722158
Cerebral haemorrhage	20.94	15.10	42	17531	57631	79669184
Joint swelling	20.52	15.10	20	17553	288626	79438189
Hypokalaemia	20.43	15.10	74	17499	143966	79582849
Loss of consciousness	20.30	15.10	82	17491	167861	79558954
Incontinence	20.28	15.10	20	17553	14144	79712671
Nausea	20.22	15.10	126	17447	957070	78769745
Dyspnoea at rest	20.10	15.10	15	17558	7287	79719528
Cardiac failure	19.84	15.10	77	17496	154765	79572050
Hanging	19.72	15.10	5	17568	158	79726657
Renal failure	19.61	15.10	92	17481	200876	79525939
Vertigo	19.02	15.10	45	17528	69037	79657778
Acquired haemophilia	18.98	15.10	9	17564	1902	79724913
Weight increased	18.83	15.10	20	17553	277366	79449449
Capillary fragility	18.44	15.10	5	17568	206	79726609
Arthropathy	18.38	15.10	8	17565	177103	79549712
Ischaemic stroke	18.31	15.10	29	17544	33102	79693713
Amaurosis fugax	18.12	15.10	7	17566	896	79725919
Subdural haematoma	18.05	15.10	28	17545	31406	79695409
Erectile dysfunction	17.90	15.10	19	17554	14645	79712170
Pulmonary interstitial emphysema syndrome	17.83	15.10	6	17567	517	79726298
Drug hypersensitivity	17.69	15.10	24	17549	298892	79427923
Generalised onset non-motor seizure	17.62	15.10	4	17569	78	79726737
Dissociation	17.60	15.10	11	17562	4010	79722805
Nasopharyngitis	17.58	15.10	18	17555	253863	79472952
Blood pressure decreased	17.55	15.10	55	17518	99411	79627404
Muscle haemorrhage	17.47	15.10	13	17560	6287	79720528
Psychomotor hyperactivity	17.40	15.10	20	17553	16829	79709986
Gynaecomastia	17.28	15.10	14	17559	7667	79719148
Dysuria	17.19	15.10	36	17537	50915	79675900
Normocytic anaemia	17.14	15.10	11	17562	4196	79722619
Hyperkeratosis	17.10	15.10	14	17559	7776	79719039
Gout	17.03	15.10	24	17549	24725	79702090
Amyotrophy	16.83	15.10	6	17567	614	79726201
Retrograde ejaculation	16.46	15.10	5	17568	310	79726505
Lactic acidosis	16.39	15.10	43	17530	70316	79656499
Drug ineffective for unapproved indication	15.90	15.10	35	17538	51203	79675612
Intraventricular haemorrhage	15.64	15.10	11	17562	4876	79721939
Dementia	15.63	15.10	23	17550	24636	79702179
Cardio-respiratory arrest	15.60	15.10	56	17517	108454	79618361
Prostate cancer	15.54	15.10	27	17546	33241	79693574
Drug ineffective	15.52	15.10	158	17415	1080755	78646060
Aortic stenosis	15.48	15.10	13	17560	7482	79719333

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	G04CA01	GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY Alpha-adrenoreceptor antagonists
ATC	G04CA51	GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY Alpha-adrenoreceptor antagonists
FDA MoA	N0000000099	Adrenergic alpha-Antagonists
FDA EPC	N0000175553	alpha-Adrenergic Blocker
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D058668	Adrenergic alpha-1 Receptor Antagonists
MeSH PA	D000317	Adrenergic alpha-Antagonists
MeSH PA	D018674	Adrenergic Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D064804	Urological Agents
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:35674	antihypertensive drugs
CHEBI has role	CHEBI:37890	alpha-adrenergic receptor blockaders

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Benign prostatic hyperplasia	indication	266569009
Orthostatic hypotension	contraindication	28651003
Torsades de pointes	contraindication	31722008
Low blood pressure	contraindication	45007003
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Cataract surgery	contraindication	110473004
Prolonged QT interval	contraindication	111975006
Angina pectoris	contraindication	194828000
Micturition syncope	contraindication	234168001
Disease of liver	contraindication	235856003	DOID:409
Intraoperative floppy iris syndrome	contraindication	418801006
Congenital long QT syndrome	contraindication	442917000
Progressive Angina Pectoris	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.09	acidic
pKa2	7.22	Basic
pKa3	0.97	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN	ANTAGONIST	Ki	8.09	CHEMBL	CHEMBL
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN	ANTAGONIST	Ki	8.44	CHEMBL	CHEMBL
Alpha-1B adrenergic receptor	GPCR	P35368	ADA1B_HUMAN	ANTAGONIST	Ki	8.55	CHEMBL	CHEMBL
Acetylcholinesterase	Enzyme	P22303	ACES_HUMAN		IC50	7.75	CHEMBL
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.83	CHEMBL
Alpha-1D adrenergic receptor	GPCR		ADA1D_RAT		Ki	8.46	CHEMBL
Alpha-1A adrenergic receptor	GPCR		ADA1A_BOVIN		Ki	7.64	CHEMBL

External reference:

ID	Source
4021396	VUID
N0000148814	NUI
D01692	KEGG_DRUG
81403-68-1	SECONDARY_CAS_RN
17300	RXNORM
C0051150	UMLSCUI
CHEBI:51141	CHEBI
CHEMBL709	ChEMBL_ID
DB00346	DRUGBANK_ID
CHEMBL1723	ChEMBL_ID
C047638	MESH_SUPPLEMENTAL_RECORD_UI
2092	PUBCHEM_CID
7109	IUPHAR_LIGAND_ID
5357	INN_ID
90347YTW5F	UNII
349912006	SNOMEDCT_US
395725004	SNOMEDCT_US
395954002	SNOMEDCT_US
4021396	VANDF
16517	MMSL
184661	MMSL
43057	MMSL
47077	MMSL
d04797	MMSL
005431	NDDF
005432	NDDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Alfuzosin hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0440-5000	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	24 sections
ALFUZOSIN HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	13668-021	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	25 sections
Uroxatral	HUMAN PRESCRIPTION DRUG LABEL	1	16590-279	TABLET, EXTENDED RELEASE	10 mg	ORAL	NDA	11 sections
Alfuzosin hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	29300-155	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	17 sections
Alfuzosin hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	29300-155	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	17 sections
Alfuzosin Hydrochlorideextended release	HUMAN PRESCRIPTION DRUG LABEL	1	31722-302	TABLET	10 mg	ORAL	ANDA	24 sections
Alfuzosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	33261-994	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	25 sections
Alfuzosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	43353-746	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Alfuzosin hydrochloride	Human Prescription Drug Label	1	43353-945	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	24 sections
Alfuzosin Hydrochloride	Human Prescription Drug Label	1	47335-956	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Alfuzosin Hydrochloride	Human Prescription Drug Label	1	47335-956	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Alfuzosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	51655-087	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Alfuzosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	51655-432	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Alfuzosin hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	51655-967	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	17 sections
Uroxatral	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5046	TABLET, EXTENDED RELEASE	10 mg	ORAL	NDA	28 sections
Alfuzosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	54868-6329	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Alfuzosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	55648-738	TABLET	10 mg	ORAL	ANDA	25 sections
Alfuzosin Hydrochloride	Human Prescription Drug Label	1	57237-114	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Uroxatral	Human Prescription Drug Label	1	59212-200	TABLET, EXTENDED RELEASE	10 mg	ORAL	NDA	27 sections
ALFUZOSIN HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	61919-349	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	18 sections
Alfuzosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2353	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Alfuzosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2353	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Alfuzosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2353	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Alfuzosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2354	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Alfuzosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2354	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Alfuzosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2354	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
Alfuzosin hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	63629-7907	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	17 sections
Alfuzosin hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	63629-7907	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	17 sections
Alfuzosin hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	63629-9155	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	17 sections
Alfuzosin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	63629-9295	TABLET, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections